参考来源: Rugo HS, Tolaney SM, Chan N, et al. Elacestrant plus abemaciclib (abema) combination in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced or metastatic breast cancer (mBC). Presented at: 2024 San Antonio Breast Cancer Symposium; December 10-1...
23. Tolaney S, Lam AQ, Mukundan S, et al:Analysis of renal function in MONARCH 1: A phase 2study of abemaciclib, a CDK4 & 6 inhibitor, asmonotherapy, in patients with HR /HER2- breastcancer, after chemotherapy for metastatic breastcancer (MBC), San Antonio Breast Cancer Symposium.Cance...
3Howlader N, Altekruse S, Li C. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5). 4Reinert T and Barrios CH. Optimal Management of Hormone Receptor Positive Metastatic Breast Cancer in 2016. TherAdv Med Oncol. 2015;...
[5]DICKLER MN,TOLANEY SM,RUGO H S,et al.MONARCH 1,a phase 2 study of abemaciclib,a CDK4 and CDK6 inhibitor,as a single agent,in patients with refractory HR+/HER2- metastatic breast cancer[J].Clin Cancer Res,2017,23(17):5218-5224. ...
Rugo HS, Tolaney SM, Chan N, et al. Elacestrant plus abemaciclib (abema) combination in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced or metastatic breast cancer (mBC). Presented at: 2024 San Antonio Breast Cancer Symposium; December 10-13, 2024;...
4 Reinert T and Barrios CH. Optimal Management of Hormone Receptor Positive Metastatic Breast Cancer in 2016. Ther Adv Med Oncol. 2015;7(6):304-20. 注: 1.相关产品或适应症尚未获批 2.
8. Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer. Clin Cancer Res. 2017 Sep 1;23(17):5218-5224....
4、Reinert T and Barrios CH. Optimal Management of Hormone Receptor Positive Metastatic Breast Cancer in 2016. Ther Adv Med Oncol. 2015;7(6):304-20. 注:
[2]Xichun Hu, Nong Yang, Jian Zhang, et al. A phase 1 study of abemaciclib in Chinese patients with advanced and/or metastatic cancers. 2020 AACR. Abstract CT164 [3]https://www.nasdaq.com/articles/eli-lilly-reports-positive-results-from-interim-analysis-of-phase-3-monarche-study-2020-06...
Collectively, we show that acquired resistance to abemaciclib leads to increased metastatic potential and increased levels of protumorigenic lysosomal proteins. Therefore, the lysosomal pathway could be a therapeutic target in advanced ER+ breast cancer....